BELLUS Health Inc – “Our Big Shift Into Rare Diseases”

NEW YORK, NY / ACCESSWIRE / April 21, 2015 / BELLUS Health Inc. (TSX: BLU) today published a new blog post on The Chairman’s Blog, written by the Company’s President and Chief Executive Officer, Roberto Bellini. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog, Mr. Bellini discusses how Bellus has evolved from a multi-focus biotech company to a developer of drugs for rare diseases, starting with those that affect the kidneys. He highlights how this area has the potential to help rare disease patients and generate the greatest value for shareholders. Read the full blog post from Mr. Bellini on TheChairmansBlog.com http://www.thechairmansblog.com/bellus-health-inc/roberto-bellini/big-shift-rare-diseases/.

About BELLUS Health Inc.

BELLUS Health is a drug development company focused on rare diseases. It has a portfolio of rare disease projects including KIACTA(TM) in Phase III for AA amyloidosis, KIACTA(TM) for sarcoidosis, clinical stage Shigamab(TM) for sHUS and a research-stage project for AL amyloidosis. The lead program KIACTA(TM) is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often leads to dialysis and death. KIACTA(TM) is partnered with global private equity firm Auven Therapeutics.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com.

SOURCE: TheChairmansBlog.com

ReleaseID: 428045